<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5069">
  <stage>Registered</stage>
  <submitdate>12/07/2015</submitdate>
  <approvaldate>12/07/2015</approvaldate>
  <nctid>NCT02497716</nctid>
  <trial_identification>
    <studytitle>Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children</studytitle>
    <scientifictitle>Single-dose Study Testing Rivaroxaban Granules for Oral Suspension Formulation in Children From 2 Months to 12 Years With Previous Thrombosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-000962-76</secondaryid>
    <secondaryid>17992</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rivaroxaban (Xarelto, BAY59-7939

Experimental: Rivaroxaban - Single arm, open label study


Treatment: drugs: Rivaroxaban (Xarelto, BAY59-7939
Single dose of reconstituted rivaroxaban granules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>AUC (area under the curve) - Only PK will be tested in central lab</outcome>
      <timepoint>4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cmax (maximum observed drug concentration) - Only PK will be tested in central lab</outcome>
      <timepoint>4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prothrombin time (PT)</outcome>
      <timepoint>Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Activated partial thromboplastin time (aPTT)</outcome>
      <timepoint>Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of major bleeding and clinically relevant non-major bleeding</outcome>
      <timepoint>From dose administration until follow up call on day 8+3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Children with an age =2 months and weight between 3 and &lt;12 kg, who have completed
             anticoagulant treatment at least 10 days prior to the planned study drug
             administration.

               -  Gestational age at birth of at least 37 weeks

               -  Oral feeding/ nasogastric/ gastric feeding for at least 10 days

          -  Normal PT and aPTT within 10 days prior to planned study drug administration

          -  Written informed consent provided and, if applicable, child assent provided</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active bleeding or high risk for bleeding, contraindicating anticoagulant therapy

          -  Planned invasive procedures, including removal of central lines, within 24 hours
             before and after single dose intake

          -  An estimate glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2

          -  Hepatic disease which is associated either with:

               -  coagulopathy leading to a clinically relevant bleeding risk, or alanine
                  aminotransferase (ALT) &gt; 5x upper level of normal (ULN), or

               -  total bilirubin &gt; 2x ULN with direct bilirubin &gt; 20% of the total.

          -  Platelet count &lt; 50 x 10^9/L

          -  Hypertension (defined as systolic and/or diastolic blood pressure &gt;95th percentile for
             age)

          -  Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, e.g., all
             human immunodeficiency virus protease inhibitors and the following azoleantimycotic
             agents: ketoconazole, itraconazole, voriconazole, and posaconazole, if used
             systemically (fluconazole is allowed)

          -  Concomitant use of strong inducers of CYP3A4, e.g., rifampicin, rifabutin,
             phenobarbital, phenytoin and carbamazepine

          -  Inability to cooperate with the study procedures

          -  Hypersensitivity to rivaroxaban

          -  Participation in a study with an investigational drug other than rivaroxaban or a
             medical device within 30 days prior to treatment

          -  History of gastrointestinal disease or surgery associated with impaired absorption</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>4/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>58</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Children's Hospital Melbourne - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Steiermark</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>HUS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Research &amp; Development, LLC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To characterize the pharmacokinetic profile of rivaroxaban administered as granules for
      suspension formulation and to document safety and tolerability</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02497716</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Bayer Clinical Trials Contact</name>
      <address />
      <phone />
      <fax />
      <email>clinical-trials-contact@bayerhealthcare.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>